Actinium Pharmaceuticals, Inc. financial data

Symbol
ATNM on NYSE
Location
100 Park Ave., 23 Rd Floor, New York, NY
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 8, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 899 % -6.59%
Debt-to-equity 151 % +40.2%
Return On Equity -57 % -75.8%
Return On Assets -56.5 % -15.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 31.2M shares +0.13%
Common Stock, Shares, Outstanding 31.2M shares +2.11%
Entity Public Float 226M USD +12.9%
Common Stock, Value, Issued 31K USD 0%
Weighted Average Number of Shares Outstanding, Basic 31.2M shares +3.63%
Weighted Average Number of Shares Outstanding, Diluted 31.2M shares +3.63%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 27.2M USD -22.8%
General and Administrative Expense 17.1M USD +47.4%
Operating Income (Loss) -44.2M USD +5.27%
Nonoperating Income (Expense) 3.21M USD -21.4%
Net Income (Loss) Attributable to Parent -41M USD +3.72%
Earnings Per Share, Basic -1 USD/shares +13.2%
Earnings Per Share, Diluted -1 USD/shares +13.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 59.9M USD -30.3%
Other Assets, Current 357K USD +58%
Assets, Current 61M USD -29.9%
Property, Plant and Equipment, Net 271K USD -41.1%
Operating Lease, Right-of-Use Asset 1.37M USD -31%
Assets 63M USD -29.9%
Liabilities, Current 8.31M USD -14.5%
Contract with Customer, Liability, Noncurrent 35M USD 0%
Operating Lease, Liability, Noncurrent 685K USD -46.7%
Liabilities 44M USD -4.39%
Retained Earnings (Accumulated Deficit) -399M USD -11.5%
Stockholders' Equity Attributable to Parent 19M USD -56.6%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 57.2M USD -16.9%
Liabilities and Equity 63M USD -29.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.57M USD -2.71%
Net Cash Provided by (Used in) Financing Activities 14.8M USD +1818%
Net Cash Provided by (Used in) Investing Activities -11K USD +85.5%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 31.2M shares +2.11%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -14.4M USD -148%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 60.3M USD -30.2%
Deferred Tax Assets, Valuation Allowance 102M USD +12.2%
Operating Lease, Liability 1.42M USD -27.6%
Payments to Acquire Property, Plant, and Equipment 11K USD -85.5%
Lessee, Operating Lease, Liability, to be Paid 1.5M USD -29.3%
Operating Lease, Liability, Current 589K USD +9.07%
Lessee, Operating Lease, Liability, to be Paid, Year Two 380K USD -39.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 643K USD +38%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 83K USD -49.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 380K USD
Deferred Tax Assets, Operating Loss Carryforwards 47.9M USD +14.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 380K USD
Operating Lease, Payments 156K USD +1.96%
Additional Paid in Capital 418M USD +4.04%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 205K USD -5.09%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%